Establishment Labs (ESTA) Expected to Announce Quarterly Earnings on Tuesday

Establishment Labs (NASDAQ:ESTA) is projected to release its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect the company to announce earnings of ($0.22) per share and revenue of $63.7980 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 8:30 AM ET.

Establishment Labs Stock Up 0.2%

Shares of NASDAQ:ESTA opened at $76.00 on Friday. The firm has a market capitalization of $2.21 billion, a PE ratio of -26.76 and a beta of 0.99. The business has a 50 day simple moving average of $70.82 and a two-hundred day simple moving average of $57.03. Establishment Labs has a 1 year low of $26.56 and a 1 year high of $78.24. The company has a debt-to-equity ratio of 15.06, a current ratio of 3.33 and a quick ratio of 2.10.

Institutional Investors Weigh In On Establishment Labs

Several large investors have recently modified their holdings of the business. ADAR1 Capital Management LLC boosted its stake in Establishment Labs by 89.0% in the fourth quarter. ADAR1 Capital Management LLC now owns 171,422 shares of the company’s stock valued at $12,493,000 after acquiring an additional 80,734 shares in the last quarter. Voloridge Investment Management LLC purchased a new stake in shares of Establishment Labs during the 4th quarter valued at $3,421,000. SummitTX Capital L.P. purchased a new stake in shares of Establishment Labs during the 4th quarter valued at $2,519,000. Tudor Investment Corp ET AL acquired a new stake in shares of Establishment Labs in the 4th quarter worth $12,852,000. Finally, Twinbeech Capital LP purchased a new position in Establishment Labs during the 4th quarter worth $214,000. Institutional investors own 72.91% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on ESTA shares. Mizuho upped their price objective on Establishment Labs from $85.00 to $90.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a research note on Monday, December 29th. Needham & Company LLC reaffirmed a “buy” rating and issued a $84.00 price target on shares of Establishment Labs in a research note on Monday, January 12th. Canaccord Genuity Group lifted their price objective on shares of Establishment Labs from $72.00 to $85.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. Finally, Citigroup upped their target price on shares of Establishment Labs from $62.00 to $75.00 and gave the stock a “neutral” rating in a research note on Thursday, December 11th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $78.86.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.